TP53 and cancer: Given the synthetic lethality between MK2 and p53 deletion in non-small-cell lung cancer models [6,7], we queried whether the lack of response of p53R273H glioblastoma cells is due to the different histological cancer type (lung vs. brain) or different p53 status (mutation vs. deletion).